| Oct 4 |
Altamira Therapeutics receives Nasdaq non-compliance letter
|
| Oct 4 |
Altamira Therapeutics Provides Update on Nasdaq Listing
|
| Sep 27 |
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
|
| Sep 24 |
Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript
|
| Sep 24 |
Altamira Therapeutics reports 1H results
|
| Sep 24 |
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
|
| Sep 20 |
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
|
| Sep 19 |
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
|
| Sep 17 |
Altamira Therapeutics prices up to $12M public offering
|
| Sep 17 |
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
|
